Voodoo medicine — cardiovascular trials jinxed in New Orleans

Patti G. , Pasceri V. , Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomised trial. J Am Coll Cardiol 2007; 49:1272-8.

Crouse JR, III , Raichlen JS , Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-• risk individuals with subclinical atherosclerosis: the METEOR Trial.JAMA 2007 ;297:1344-53.

Sacks FM The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43.

Wierzbicki AS Have we forgotten the pivotal role of highdensity lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005; 21:299-306.

Wierzbicki AS Lipid-altering agents: the future. Int J Clin Pract 2004;58:1063-72.

Wierzbicki AS Low HDLcholesterol: Common and under-treated, but which drug to use? Int J Clin Pract 2006 ; 60:1149-53.

Nissen SE , Tsunoda T. , Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-300.

Wierzbicki AS FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006 ;60:442-9.

Keech A. , Simes RJ , Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the E FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61.

Chapman MJ , Assmann G. , Fruchart JC et al. Raising highdensity lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid -a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20:1253-68.

Forrester JS , Makkar R. , Shah PK Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111: 1847-54.

Tardif JC , Cote G. , Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72.

Tardif JC , Gregoire J. , Schwartz L. et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8.

Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-8.

Jackson G. Stable angina: two important trials-RITA-2 and ACIP( Asymptomatic Cardiac Ischaemia Pilot). Int J Clin Pract 1997;51:419-20.

Boden WE , O'rourke RA , Teo KK et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007; 350:1503-16.

Henderson RA , Pocock SJ , Clayton TC et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-70.